
Healthy human T cell
via NAID
Bioengineers at the University of California San Diego have developed a cancer immunotherapy that pairs ultrasound with cancer-killing immune cells to destroy malignant tumors while sparing normal tissue.
The new experimental therapy significantly slowed down the growth of solid cancerous tumors in mice.
The team, led by the labs of UC San Diego bioengineering professor Peter Yingxiao Wang and bioengineering professor emeritus Shu Chien, detailed their work in a paper published Aug. 12 in Nature Biomedical Engineering.
The work addresses a longstanding problem in the field of cancer immunotherapy: how to make chimeric antigen receptor (CAR) T-cell therapy safe and effective at treating solid tumors.
CAR T-cell therapy is a promising new approach to treat cancer. It involves collecting a patient’s T cells and genetically engineering them to express special receptors, called CAR, on their surface that recognize specific antigens on cancer cells. The resulting CAR T cells are then infused back into the patient to find and attack cells that have the cancer antigens on their surface.
This therapy has worked well for the treatment of some blood cancers and lymphoma, but not against solid tumors. That’s because many of the target antigens on these tumors are also expressed on normal tissues and organs. This can cause toxic side effects that can kills cells—these effects are known as on-target, off-tumor toxicity.
“CAR T cells are so potent that they may also attack normal tissues that are expressing the target antigens at low levels,” said first author Yiqian (Shirley) Wu, a project scientist in Wang’s lab.
“The problem with standard CAR T cells is that they are always on—they are always expressing the CAR protein, so you cannot control their activation,” explained Wu.
To combat this issue, the team took standard CAR T cells and re-engineered them so that they only express the CAR protein when ultrasound energy is applied. This allowed the researchers to choose where and when the genes of CAR T cells get switched on.
“We use ultrasound to successfully control CAR T cells directly in vivo for cancer immunotherapy,” said Wang, who is a faculty member of the Institute of Engineering in Medicine and the Center for Nano-ImmunoEngineering, both at UC San Diego. What’s exciting about the use of ultrasound, noted Wang, is that it can penetrate tens of centimeters beneath the skin, so this type of therapy has the potential to non-invasively treat tumors that are buried deep inside the body.
The team’s approach involves injecting the re-engineered CAR T cells into tumors in mice and then placing a small ultrasound transducer on an area of the skin that’s on top of the tumor to activate the CAR T cells. The transducer uses what’s called focused ultrasound beams to focus or concentrate short pulses of ultrasound energy at the tumor. This causes the tumor to heat up moderately—in this case, to a temperature of 43 degrees Celsius (109 degrees Fahrenheit)—without affecting the surrounding tissue. The CAR T cells in this study are equipped with a gene that produces the CAR protein only when exposed to heat. As a result, the CAR T cells only switch on where ultrasound is applied.
The researchers put their CAR T cells to the test against standard CAR T cells. In mice that were treated with the new CAR T cells, only the tumors that were exposed to ultrasound were attacked, while other tissues in the body were left alone. But in mice that were treated with the standard CAR T cells, all tumors and tissue expressing the target antigen were attacked.
“This shows our CAR T-cell therapy is not only effective, but also safer,” said Wu. “It has minimal on-target, off-tumor side effects.”
The work is still in the early stages. The team will be performing more preclinical tests and toxicity studies before it can reach clinical trials.
Original Article: Ultrasound remotely triggers immune cells to attack tumors in mice without toxic side effects
More from: University of California San Diego | Shanghai Jiao Tong University | Prince of Songkla University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Ultrasound cancer immunotherapy
- Mild Side Effects Predict Response to Immunotherapy
Effective immunity requires the body to know when to ramp up the immune system when a threat, such as abnormal cells that could develop into cancer. On the other hand, the body also needs to know when ...
- Two-pronged immunotherapy eliminates metastatic breast cancer in mice
p38MAPKa stromal reprogramming sensitizes metastatic breast cancer to immunotherapy. Cancer Discovery , 2023; DOI: 10.1158/2159-8290.CD-22-0907 Cite This Page : ...
- Synthetic protein tweak could lead to universal cancer immunotherapy
Scientists at ETH Zurich have made a breakthrough towards designing an off-the-shelf treatment for immunotherapy against cancer. A synthetic protein tweak can allow immune cells from any donor to ...
- Can Lymph Nodes Boost the Success of Cancer Immunotherapy?
Cancer treatment routinely involves taking out lymph nodes near the tumor in case they contain metastatic cancer cells. But new findings from a clinical trial by researchers at UC San Francisco and ...
- How gut bacteria can boost cancer immunotherapy efficacy
Share on Pinterest A study in mice suggests that doctors may be able to use gut bacteria to boost some immunotherapy treatments ... the immune system to kill cancer cells. Further study is ...
Go deeper with Google Headlines on:
Ultrasound cancer immunotherapy
[google_news title=”” keyword=”ultrasound cancer immunotherapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
CAR T-cell therapy
- Carina Biotech to Present Preclinical Data Evaluating LGR5-Targeted CAR-T Cell Therapy in Colorectal Cancer Models at 2023 AACR
Preclinical data demonstrates that LGR5-targeting CAR-T therapy has high potential as an effective therapeutic for human colorectal cancer. LGR5-targeting CAR-T cells effectively kill LGR5-expressing ...
- Researchers discover source of T cell exhaustion
The discovery, reported online today in the journal Molecular Cell, suggests that targeting certain of these complexes, either by gene-cutting technologies such as CRISPR or with targeted drugs, could ...
- CAR T-Cell therapy Market Is Projected to Reach $6.1 Billion by 2031 | Updated Research By AMR
CAR T-cell therapy is a type of immunotherapy that uses genetically engineered T-cells to treat certain types of cancer. T-cells are a type of white blood ...
- Gilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma Patients
Kite, a Gilead Science Inc (NASDAQ: GILD) company, announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement ...
- 2023-2029 CAR-T Cell Therapy Market Size and Consumption Analysis by Region | Latest Report by Absolute Reports
Mar 21, 2023 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global "CAR-T Cell Therapy ...
Go deeper with Google Headlines on:
CAR T-cell therapy
[google_news title=”” keyword=”CAR T-cell therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]